The following content is sponsored by Americans for a limited government:
Forcing European countries to remove pharmaceutical price controls through strong trade agreements will reduce the trade deficit while keeping the US ahead of China.
What industry does America currently control Europe and China? Development of life-saving treatment for chronic diseases. America is an indisputable world champion of pharmaceutical innovation, the title that saved millions of lives and promoted the development of groundbreaking treatments.
However, this advantage is at risk when adopting price control and death panels imposed by European governments. While medicines need to be more affordable, copying the European model of socialism is not the “first America” solution. Instead, it kills innovation and competition, harms our businesses, and leaves the US transferring our leadership in biomedical innovation to China.
For decades, Europe has been a leader in drug development and home to pioneering research and development in the industry. However, in recent years, drug price control has been achieved. It's suffocating This innovation and ruined their industry. The once thriving European companies have moved their research hub to the US. The US free market is rewarding investments in cutting-edge treatments. There is in this shift He helped me The United States will become the global pharmaceutical powerhouse, responsible for more than half of new drug discoveries.
Incredibly, previous liberal leaders like Joe Biden and Nancy Pelosi have tried to implement European-style price controls in the US, claiming that doing so would reduce medical costs. But making it happen will erode the innovative edge, like in Europe. The reality is simple. When the country imposes price controls on drugs, these price controls drain investments. This will reduce domestic manufacturing and research investments, ultimately limiting treatments for cancer, Alzheimer's disease, heart disease and diabetes. It reduces life-saving treatments, increases waiting times for new drugs, and fewer types of work America needs.
There is a better way. To resolve this issue, President Trump could renegotiate international trade agreements and pressure foreign governments to pay fair market prices. Just as he forced his NATO allies to “pay their fair shares,” President Trump can hold European countries accountable for paying fair prices for drugs and drug development. In fact, one study shows that lifting up European and other OECD price management will increase revenue by $254.1 billion, most of which is sent to American companies. In one move, President Trump can lower the trade deficit with Europe, reduce the costs of American patients, and unleash new treatments for the worst disease.
There is another aspect to this that should not be overlooked. It is the country that is most likely to win if the US adopts prescription drugs in China's European price control. China is waiting to fill the void of inevitably resulting innovation. China's pharmaceutical industry has already entered the US market. send FDA application for new drugs. Weakening the US industry through price control risks transferring leadership to China, a country whose track record on quality control, transparency and intellectual property theft gives policymakers a serious suspension.
Do we really want to be in the position waiting for China for the next breakthrough cancer treatment or Alzheimer's medication? This is the risk that will be carried out if we accept price management that will give back research and development and kill innovation.
However, the risk of relying on China goes beyond mere innovation. Proliferation of Untested imitation China's weight loss drugs have already issued warnings about safety and supply chain vulnerabilities. If we become dependent on China for legitimate drugs, we are at risk. Countries that have conspired to export fentanyl to our communities should not rule the future of American pharmaceuticals.
America's first approach to drug pricing does not mean importing a failed European socialist model. It means strengthening our own industry, promoting innovation and ensuring that the United States remains a global leader in medical advancement. Price control may sound like a simple fix, but it is supplied at a cost that weakens our economic strength, undermines our ability to develop new treatments, placing the future of our medicines in foreign enemies.
President Trump can lower US drug prices by knocking out patient-use insurance brokers and hospital conglomerates. At the same time, he can force European countries to drop price controls for drugs and pay a fair share, like with NATO. Our patients, our economy, and our national security depends on it.
